← Back to All Filings

Fidelity Reports 10.3% Stake in Roivant Sciences (~$2.1B Position)

High SignificanceMarch 6, 2026 at 10:07:00 AM EST

Roivant Sciences Ltd.

$ROIVSCHEDULE 13G/ACIK: 0001635088

Subscribe to track ROIV

Premium users can add ticker alerts and receive realtime notification updates.

Filing Summary

Fidelity Reports 10.3% Stake in Roivant Sciences (~$2.1B Position)

Company: Roivant Sciences Ltd. Form: SCHEDULE 13G/A | Filed: 2026/03/06 Significance: High

Insider: FMR LLC Relationship: >10% Owner (Institutional)

Holdings Update: • Security: COMMON STOCK • Shares Owned: 73,641,253 • % of Class: 10.3% • Est. Position Value: ~$2.13 Billion

Key Insight: Fidelity (FMR LLC) confirms a massive strategic position, holding over 10% of Roivant's outstanding shares, valued at approximately $2.13 billion based on current market cap.

Market Context: This filing represents a continued high-conviction holding by one of the world's largest asset managers in the $20B biotech company.

View Full Filing

Comprehensive Analysis

SEC Filing Analysis: Roivant Sciences Ltd.

Executive Summary

  • Trading Significance: High
  • Key Takeaway: Fidelity (FMR LLC) reports a massive 10.3% ownership stake, cementing its status as a top institutional holder.
  • Market Impact: Neutral to Bullish (Confirms long-term institutional support).

Company Information

FieldValue
CompanyRoivant Sciences Ltd.
CIK0001635088
Market Cap$20.71 Billion
IndustryPharmaceutical Preparations

Insider Information

FieldValue
NameFMR LLC (Fidelity)
CIK0000315066
Relationship>10% Beneficial Owner
TypeInstitutional Investor

Transaction Details

FieldValue
Form TypeSCHEDULE 13G/A
Event Date2026-02-27
Security TypeCOMMON STOCK
Shares Owned73,641,253
Ownership %10.3%

Financial Impact Assessment

Position Materiality

MetricValue
Total Shares Outstanding715,700,000
Insider Shares Owned73,641,253
% of Shares Outstanding10.29%
Estimated Position Value~$2.13 Billion
Materiality AssessmentHighly Significant

Impact Evaluation

  • Market Cap Context: For a $20.71B company, a $2.1B position represents a foundational institutional stake.
  • Ownership Concentration: Fidelity controls >10% of the float, significantly reducing available supply and indicating high conviction.
  • Transaction Significance: While this is an amendment (13G/A) reporting a standing position, the maintenance of a >10% stake is a critical signal of stability.

Market Impact Analysis

Stock Impact Prediction

  • Direction: Neutral/Bullish
  • Reasoning: The filing confirms that Fidelity has not liquidated its massive position. Crossing or maintaining the 10% threshold often signals long-term commitment rather than short-term trading.

Volume & Sentiment

  • Expected Volume Impact: Low (Reporting existing holdings).
  • Sentiment Indicator: Bullish. Continued support from a top-tier asset manager validates the company's valuation and prospects.

Investment Insights

Positive Market Indicators

  • Institutional Validation: Fidelity's 10.3% stake is a strong vote of confidence in Roivant's pipeline and management.
  • Supply Constraint: With >10% of shares locked in this single institutional position, the effective float is reduced.

Key Takeaways

  1. FMR LLC (Fidelity) is a dominant shareholder with 10.3% ownership.
  2. The position is valued at over $2.1 billion, making it a critical holding for the fund.
  3. This 13G/A filing updates the market on the size of this stake as of Feb 27, 2026, confirming no major exit has occurred.

Additional Context

Transaction Notes

  • Filing Type: Schedule 13G/A indicates this is an amendment to a previous filing, likely updating the share count or percentage ownership.
  • Joint Filing: Filed on behalf of FMR LLC and Abigail P. Johnson, indicating control through the Johnson family's ownership of FMR.
Topics:#Roivant#Fidelity#InstitutionalInvestor#Biotech#StockMarket#HighSignificance#13G#SmartMoney#Investing

Get Real-Time Alerts

Join our community to receive instant notifications when high-significance filings are published

Important Disclaimer

This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.

Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.